TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

LATEST NEWS

Chinese Biotech Start-up Antengene Plans Hong Kong IPO, Targeting Gaps In Treatment Of Prevalent Asian Cancers
Play
INVESTING

Acceleron Soars in After-Hours Trading on Positive Trial Results for Hypertension Treatment

PRESS RELEASES

Acceleron To Participate In The 39th Annual J.P. Morgan Healthcare Conference On January 11, 2021

PRESS RELEASES

Acceleron Receives Orphan Designation From The European Commission (EC) For Sotatercept In Pulmonary Arterial Hypertension (PAH)

PRESS RELEASES

Acceleron Presents Preliminary Interim Data From The SPECTRA Phase 2 Trial Of Sotatercept In Pulmonary Arterial Hypertension (PAH) At The 2020 American Heart Association Scientific Sessions

PRESS RELEASES

Acceleron Presents New Data From The PULSAR Phase 2 Trial, Preclinical Research On Sotatercept In Pulmonary Arterial Hypertension (PAH) At The 2020 American Heart Association (AHA) Scientific Sessions

PRESS RELEASES

Acceleron Announces Third Quarter 2020 REBLOZYL® Net Sales

PRESS RELEASES

Acceleron Announces REBLOZYL® (luspatercept-aamt) Virtual Presentations At The 62nd American Society Of Hematology Annual Meeting

PRESS RELEASES

Acceleron To Webcast Third Quarter 2020 Operating And Financial Results On November 5, 2020

PRESS RELEASES

Health Canada Approves REBLOZYL® (luspatercept), New Class Of Treatment For Adult Patients Living With Beta Thalassemia

PRESS RELEASES

Acceleron To Host Webcast Outlining The Design Of Its Registrational Phase 3 STELLAR Trial Of Sotatercept In Pulmonary Arterial Hypertension (PAH) On October 2, 2020

PRESS RELEASES

Acceleron Appoints Laura J. Hamill To Its Board Of Directors

PRESS RELEASES

Acceleron Announces Second Quarter 2020 REBLOZYL® Net Sales

PRESS RELEASES

Acceleron To Webcast Second Quarter 2020 Operating And Financial Results On August 6, 2020

PRESS RELEASES

Acceleron Announces Closing Of Public Offering Of Common Stock And Exercise Of Underwriters' Option To Purchase Additional Shares

PRESS RELEASES

XLRN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Acceleron Pharma Inc. And Encourages Investors To Contact The Firm

PRESS RELEASES

Acceleron Announces Pricing Of Public Offering Of Common Stock

PRESS RELEASES

Acceleron Announces Proposed Public Offering Of Common Stock

PRESS RELEASES

European Commission Approves Reblozyl (luspatercept) For The Treatment Of Transfusion-Dependent Anemia In Adult Patients With Myelodysplastic Syndromes Or Beta Thalassemia

PRESS RELEASES

Acceleron Appoints Christopher Hite To Its Board Of Directors

PRESS RELEASES

Acceleron Announces Oral Presentation Of PULSAR Phase 2 Trial Results In Virtual American Thoracic Society 2020 Conference Session On June 24, 2020

PRESS RELEASES

Acceleron Announces Publication In Science Translational Medicine Describing The Underlying Biology Behind Sotatercept's Potential As A Novel Therapy In Pulmonary Arterial Hypertension

PRESS RELEASES

Acceleron To Webcast First Quarter 2020 Operating And Financial Results On May 11, 2020

PRESS RELEASES

Acceleron Receives Priority Medicines (PRIME) Designation From European Medicines Agency (EMA) For Sotatercept In Pulmonary Arterial Hypertension

PRESS RELEASES

Reblozyl (luspatercept) Receives Positive CHMP Opinion For The Treatment Of Adults With Anemia In Beta Thalassemia And Myelodysplastic Syndromes

PRESS RELEASES

Acceleron Receives FDA Breakthrough Therapy Designation For Sotatercept In Pulmonary Arterial Hypertension